You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202311 - 202320 of 207725 results
  1. Methioninase Loaded Nanoshells for Systemic Methionine Depletion Therapy

    SBC: DEVACELL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Systemic depletion of the essential amino acid methionine has been shown to be a potentially powerful therapeutic approach to many cancer types. A critical gene in the methionine salvage pathway, MTAP, is co- deleted along with the chromosomally co-located CDKN2A gene in a large number of solid tumors. However, attempts to use methioninase as a therapy failed b ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Targeted siRNA NanoJackets for the Personalized Treatment of Breast Cancer

    SBC: KEYSTONE NANO, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Most current chemotherapeutics have non-specific mechanisms of action and poor biodistribution profiles which result in dose-limiting toxicities tha prevent optimal efficacy from being obtained. Ribonucleic acid interference (RNAi) has the potential to be a safe, selective and personalized treatment approached for a variety of genetic-based diseases, including ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Efficacy and resistance mechanisms of LD-aminopterin in psoriasis

    SBC: Syntrix Biosystems, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Psoriasis is a chronic, genetically influenced, remitting and relapsing scaly and inflammatory skin disorder that affects 1-3% of the world's population, resulting in total annual costs of 5.2 billion in the United States in 2012. Approximately 20% of patients with moderate-to-severe chronic plaque psoriasis require phototherapy and/or a variety of system ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Combinatorial RXR-based therapeutics for Alzheimer's disease

    SBC: REXCEPTOR, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): The principle objective of this application is the development of safer and more effective combinatorial therapy for AD. ReXceptor, Inc. is developing new therapeutics for the treatment of AD based on stimulating the physiological clearance mechanisms of soluble forms of A from the brain. Bexarotene is an agonist of the ligand-activated transcription factor, r ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics

    SBC: NEUROP, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate receptors (NMDARs), glutamate receptor subtypes found at nearly all vertebrate excitatory synapses. NMDARs are critically involved in many aspects of nervous system function, including learning and me ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of small near-infrared laser system capable of improving immune respo

    SBC: SEMINEX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad and long-term objective of this project is to amplify the effectiveness of vaccines without the use of chemical or biological adjuvants. We will address this objective by demonstrating the feasibility for small laser- based devices to enhance responses to intradermal vaccination. A number of investigators have shown that a promising new way to make va ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Surface-covering gels for broad-spectrum antimicrobial protection following open

    SBC: SONORAN BIOSCIENCES INC            Topic: NIAMS

    DESCRIPTION (provided by applicant): About 3-4% of all fractures are estimated to be open fractures, where the fracture is exposed through defects in the skin and soft tissues. This equates to about 250,000 open fractures in the United States annually. Open fractures present a high risk of infection. Infection results in considerable financial burden to both the patient an healthcare system, requ ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Feasibility of Non-surgical Implant Adjustment

    SBC: Apto Orthopaedics Corportation            Topic: NIAMS

    DESCRIPTION (provided by applicant): While minimally invasive surgery has transformed the practice of surgery, access to implants for removal or alteration still requires surgery which generates risk and high cost. A next-generation approach is non-invasive, where implants are adjusted without an incision. There are clear applications in all fields of surgery, but particulary in orthopaedics wher ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government